INTRODUCTION
Prothrombin 20210 G>A mutation is considered the second most frequent inherited thrombophilia. 1 The frequency of heterogeneous carriers in general population is 2-5% and in patients with VTE -6-18%. 2 The latter frequency varies between 5.9% and 32.1% in Bulgarian studies. 3, 4 The role of a homozygous carrier of 20210 G>A mutation as a risk factor for VTE is not well studied because of its rarity. Clinical experience is based on case reports. 5, 6 A 2006 review article reported 70 homozygous cases worldwide. 7 We report a family with two homozygous members. To our knowledge this is the fi rst reported case of homozygous prothrombin mutation carriers in Bulgaria and the other Balkan countries.
CASE REPORT
A Prothrombin 20210 G>A mutation is the second most frequent inherited factor increasing the risk for developing venous thromboembolism (VTE). The risk for VTE in homozygous carriers of this mutation is not well studied because of their rarity are rare. We report a case of a homozygous carrier of prothrombin mutation: a young man with massive pulmonary embolism, and his family -an asymptomatic homozygous sister, heterozygous parents with asymptomatic mother, and father with history of deep venous thrombosis (DVT). To our knowledge, this is the fi rst reported case of homozygous prothrombin mutation carriers in Bulgaria and the other Balkan countries. We conclude that the homozygous prothrombin mutation creates predisposition for VTE that can manifest or not depending on additional factors, one of which could be male gender. the cavities of the main right and left pulmonary arteries and thrombi in all segmental branches bilaterally (Fig. 1) . (Fig. 3) 
unprovoked DVT at the age of 47. He had discontinued treatment with oral anticoagulant 3 years before. No recurrence of VTE. The thrombophilia examination showed him to be a heterozygous carrier of prothrombin G20120A, PAI-1 4G/5G, A1298C and C677T mutations and absence of Leiden mutation

Laboratory examinations for inherited and acquired thrombophilia (thrombophilic examination) found (Fig. 2): homozygous prothrombin 20210AA mutation; heterozygous carrier of PAI-1 4G/5G, A1298C and C677T mutations; absence of Leiden mutation, normal values of antithrombin III (AT III) -88.5%, protein C (Pr. C) -114.8% and protein S (Pr. S) -130%. Antiphospholipid antibodies were not found. Homocysteine -13.03 μmol/l (N 0 -15).
We examined the members of his family: both parents and sister. All live together, share the same lifestyle, work at computers and never smoked.
The sister: 24 years old, doesn't take contraceptives, nulligravida, no history of operations, fully asymptomatic. The thrombophilia examination showed her to be a homozygous carrier of prothrombin 20120AA mutation and heterozygous carrier of A1298C and C677T variants of MTHFR gene, normal carrier of PAI-1 5G/5G gene and absence of Leiden mutation (Fig. 2) (Fig. 3) . AT III, Pr. C and Pr. S levels were within normal ranges. Antiphospholipid antibodies were negative. Prothrombin time was 13.4 sec, homocysteine -10.13 μmol/l.
The father: a 51-year-old man with history of
DISCUSSION
The patient we report is a carrier of several inherited abnormalities. Except for the prothrombin mutation, they are all considered weak thrombophilic factors.
That is why we suggest that prothrombin 20210AA mutation in this patient is the leading cause of the massive pulmonary embolism. But his sister is the same age, has similar inherited abnormalities and is asymptomatic. Is this by chance or not? The same holds for their parents: the father and the mother are the same age and have similar abnormalities, but only the father had a VTE event, although the mother had precipitating factors such as pregnancies and operation. We hypothesize that the male gender is more susceptible to inherited thrombophilic factors compared to women in equal other circumstances. Our contention is consistent with strong evidence for twice as high risk of recurrence of VTE in men as in women. 8 
CONCLUSION
The hom ozygous prothrombin 20210G ›A mutation creates predisposition to thrombotic events that can manifest depending on additional factors. We hypothesize that the male gender is one of these factors. Our two cases can be added to the small pool of reported cases of prothrombin 20210AA mutation carriers worldwide.
